Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MGTA 145

Next Previous
Drug Profile

MGTA 145

Alternative Names: GRO beta; GROß; GroβT; MGTA-145

Latest Information Update: 09 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Magenta Therapeutics
  • Developer bluebird bio; Dianthus Therapeutics
  • Class Antineoplastics; Immunotherapies; Proteins
  • Mechanism of Action Interleukin-8B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stem cell mobilisation
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sickle cell anaemia; Stem cell mobilisation

Most Recent Events

  • 28 Feb 2023 Magenta Therapeutics terminates the collaboration agreement with bluebird in February 2023
  • 02 Feb 2023 Magenta Therapeutics terminates a phase II trial due to a business decision not to proceed, and not due to any safety issue in Sickle cell anaemia (Combination therapy) in USA (IV) (NCT05445128)
  • 31 Dec 2022 Magenta Therapeutics has patents pending for MGTA 145 in USA and other countries before December 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top